Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability and Food Effect of Berotralstat Formulations
NCT03202784Phase 1Completed
- Sponsor
- BioCryst Pharmaceuticals, Inc.
- Start
- Feb 2017
- Primary completion
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of berotralstat in hereditary angioedema (HAE) (3 arms), sponsored by BioCryst Pharmaceuticals, Inc. Primary endpoints: Maximum Plasma Concentration at 72 hours, Area Under the Curve to Last Measurable Concentration at 72 hours and 1 more. Started Feb 2017; status: completed.
02
Drugs
berotralstat
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on NCT03202784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03202784.